PPARG and lip and oral cavity carcinoma: Wright et al. researched human oral cancer cell lines CA-9-22 and NA, which were treated with the PPAR activators eicosatetraenoic acid (ETYA), 15-deoxy-δ-12,14-prostaglandin J2 (PG-J2), thiazolidinedione, and ciglitazone, and then tested on their ability to functionally activate PPARγ luciferase reporter gene constructs.